The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
Table 1
Patient clinical and serological features before and after tocilizumab treatment.
Pt
Gender
Age
ESR (mm/h) at baseline
ESR (mm/h) at follow-up
CRP (mg/dl) at baseline
CRP (mg/dl) at follow-up
Oral PDN dose at baseline (mg)
Oral PDN dose at follow-up (mg)
Follow-up (months)
AE leading to discontinuation
1
F
65
62
5
4.3
0.2
50
5
6
—
2
F
64
111
33
14.8
0.44
50
5
3
Leukopenia
3
F
70
62
6
4.35
0.08
50
5
6
—
4
F
74
80
2
6.9
0.1
50
5
12
—
5
F
78
50
2
5.08
0.06
62.5
12.5
3
Metastatic melanoma
6
F
56
103
5
14.1
0.04
50
2.5
12
—
7
F
77
89
2
6.73
0.08
62.5
0
12
—
8
M
60
53
31
1.24
0.21
62.5
1.25
12
—
9
F
85
120
4
4
0.01
50
0
6
—
10
M
77
103
35
8.9
0.44
50
5
12
—
11
M
65
102
8
4
0.3
75
10
6
—
AE: adverse events; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PDN: prednisone; patients who underwent three boluses of 1000 mg methylprednisolone before being treated with tocilizumab and oral PDN.
